Kainos Medicine, Inc. (KOSDAQ:284620)
South Korea · Delayed Price · Currency is KRW 1,087.00
-105.00 (-8.81%)
At close: Aug 14, 2025
Kainos Medicine Revenue
In the year 2025, Kainos Medicine had annual revenue of 1.17B KRW with 98.46% growth. Kainos Medicine had revenue of 304.09M in the quarter ending December 31, 2025, with 326.34% growth.
Revenue
1.17B
Revenue Growth
+98.46%
P/S Ratio
30.35
Revenue / Employee
n/a
Employees
n/a
Market Cap
35.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.17B | 581.27M | 98.46% |
| Dec 31, 2024 | 590.37M | 323.05M | 120.85% |
| Dec 31, 2023 | 267.31M | 137.29M | 105.59% |
| Dec 31, 2022 | 130.02M | -1.53B | -92.18% |
| Dec 31, 2021 | 1.66B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| J2KBIO | 32.97B |
| NGeneBio | 21.24B |
| ADBiotech | 12.90B |
| MOA Life Plus | 11.22B |
| Eutilex.Co.,Ltd | 10.54B |
| EyeGene | 3.57B |
| SCM Lifescience | 1.54B |
| Epibiotech | 449.62M |